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The relationship between tumour stage, grade (Fuhrman), performance status (ECOG), a combined score (UCLA Integrated Staging
System, UISS), systemic inflammatory response (elevated C-reactive protein concentration), and cancer-specific survival was
examined in patients undergoing potentially curative resection for renal clear cell cancer (n¼100). On univariate survival analysis, sex
(P¼0.050), tumour stage (P¼0.001), Fuhrman grade (Po0.001), UISS (Po0.001), C-reactive protein (P¼0.002) were significant
predictors of survival. On multivariate analysis with sex, UISS and C-reactive protein entered as covariates, only UISS (HR 2.70, 95%
CI 1.00–7.30, P¼0.050) and C-reactive protein (HR 4.00, 95% CI 1.21–13.31, P¼0.024) were significant independent predictors of
survival. The presence of a preoperative systemic inflammatory response predicts poor cancer-specific survival in patients who have
undergone potentially curative resection for renal clear cell cancer.
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Renal cell cancer, although the twelfth most common cause of
cancer death is one of the most lethal urological cancers. Each
year in the UK, there are approximately 3500 new cases and
approximately 30% of patients present with metastases. Overall
survival is poor; even in those who undergo potentially curative
resection, only approximately half survive 5 years (Cancerstats,
www.cancerresearchuk.org).
The ideal prognostic score for patients undergoing potentially
curative resection of a primary renal cancer should clearly
distinguish those who will eventually succumb to the disease from
those who are cured. While TNM stage has been widely used,
it fails to provide clear separation between these groups. This has
lead to the development of a number of cumulative prognostic
scores including TNM stage. TNM stage has been combined with
tumour grade and performance status to form the UCLA
Integrated Staging System (UISS, Zisman et al, 2002).
It is recognised that in addition to tumour stage and
proliferative activity, disease progression is dependent on a
complex interaction of the tumour and host inflammatory
response (Balkwill and Mantovani, 2001; Coussens and Werb,
2002; Vakkila and Lotze, 2004). Recently, the systemic inflamma-
tory response, as evidenced by elevated circulating concentrations
of C-reactive protein, has been shown to be a stage independent
prognostic factor in patients undergoing potentially curative
resection for colorectal cancer (McMillan et al, 2003), pancreatic
cancer (Jamieson et al, 2005) and urinary bladder cancer (Hilmy
et al, 2005).
The aim of the present study was to examine the prognostic
value of the systemic inflammatory response in patients under-
going potentially curative resection for renal cancer.
PATIENTS AND METHODS
Patients with renal clear cell cancer, who, on the basis of surgical
findings and preoperative computed tomography of chest abdo-
men and pelvis underwent potentially curative resection between
August 1996 and November 2004 in the West of Scotland, were
included in the study. No patient had metastatic disease and the
tumour confined to the kidney. In the case of T3/T4 tumours all
macroscopic tumour was removed with clear resection margins.
Patients were staged pathologically according to the 1997 UICC
TNM classification of renal tumours (Sobin and Wittekind, 1997).
Tumours were graded according to criteria set out by Fuhrman
et al (1982). Tumour stage, grade and ECOG-ps were collated into
the UISS (Zisman et al, 2002, Table 1).
Data for 1996–2000 (n¼57) were collected retrospectively and
that for 2001–2004 (n¼43) prospectively. Clinical stage and
performance status (Eastern Cooperative Oncology Group,
ECOG-ps) were recorded prior to surgery. Also, routine laboratory
measurement of C-reactive protein was carried out.
The Research Ethics Committee of North Glasgow NHS Trust
approved the study.
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reactive protein concentration was performed. The limit of
detection of the assay was a C-reactive protein concentration
lower than 6mgl
 1. The coefficient of variation, over the range of
measurement, was less than 5% as established by routine quality
control procedures. C-reactive protein measurement of greater
than 10mgl
 1 was considered to indicate the presence of systemic
inflammatory response (O’Gorman et al, 2000).
Statistics
Comparisons between groups of patients were carried out using
contingency table analysis (X
2) as appropriate. Survival analysis
was performed using the Cox’s proportional-hazards model.
Deaths up to the end of October 2005 were included in the
analysis. Multivariate survival analysis was performed using a
stepwise backward procedure to derive a final model of the
variables that had a significant independent relationship with
survival. To remove a variable from the model, the corresponding
P-value had to be greater than 0.10. Analysis was performed using
SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of patients with renal cancer who underwent
potentially curative resection (n¼100) are shown in Table 2. The
majority was male, over the age of 60 years, had good performance
status, low T stage (median tumour volume 178cm
3) and were
defined as UISS intermediate risk. Approximately, 40% had an
elevated C-reactive protein concentration (410mgl
 1).
The minimum follow-up was 12 months; the median follow-up
of the survivors was 59 months. During this period 25 patients
died; 18 patients of their cancer and seven of intercurrent disease.
On univariate survival analysis, sex (P¼0.050), tumour stage
(Pp0.001), Fuhrman grade (Po0.001), UISS (Po0.001) and C-
reactive protein (Po0.01) were significant predictors of cancer-
specific survival.
On multivariate analysis with sex, tumour stage, Fuhrman grade,
performance status and C-reactive protein entered as covariates,
only sex (HR 0.25, 95% CI 0.06–0.99, P¼0.048), Fuhrman grade
(HR 2.91, 95% CI 1.29–6.56, P¼0.010) and C-reactive protein (HR
7.67, 95% CI 1.64–35.84, P¼0.010) were significant independent
predictors of cancer-specific survival.
On multivariate analysis with sex, UISS and C-reactive protein
entered as covariates, only UISS (HR 2.70, 95% CI 1.00–7.30,
P¼0.050) and C-reactive protein (HR 4.00, 95% CI 1.21–13.31,
P¼0.024) were significant independent predictors of cancer-
specific survival. A greater proportion of females compared with
males had Fuhrman grade I tumours (10 vs 29%, P¼0.030, Fisher’s
exact test).
The relationship between the systemic inflammatory response
and the clinicopathological characteristics are shown in Table 3.
There was no significant difference in age or sex between the
inflammatory and noninflammatory groups. An elevated C-
reactive protein was associated with a greater number of patients
with advanced tumour stage (Po0.01), increased grade (Po0.05),
poorer performance status (Po0.01) and consequently a high UISS
(Po0.01). Those patients with an elevated preoperative C-reactive
protein concentration (410mgl
 1) had a mean cancer-specific
survival of 71 months compared with 96 months (Po0.001) in
those patients with a C-reactive protein concentration in the
normal range (p10mgl
 1).
In those patients with a UISS risk classified as ‘low’ or
‘intermediate’ (n¼91) an elevated C-reactive protein concentra-
tion was associated with a decrease in cancer-specific survival
(P¼0.008, Figure 1).
DISCUSSION
Surgical resection remains the only prospect for long-term survival
in patients with renal clear cell cancer. Currently, in patients
undergoing surgery prognosis is based on tumour stage and grade
and performances status (UISS, Zisman et al, 2002). In the present
study, the preoperative measurement of C-reactive protein
provided additional prognostic information.
Table 1 UISS prognostic algorithm in N0, M0 nephrectomised patients (Zisman et al, 2002)
T Stage 1 2 3 4
Grade 1–2 3–4 Any 1 41 Any
ECOG 0 X10X1 Any 0 X10X1 Any
Risk Low Intermediate High
Table 2 The relationship between clinicopathological characteristics and
cancer-specific survival in patients undergoing potentially curative resection
for renal cancer
Patients
(n¼100)
Hazard ratio
(95% CI) P-value
Age group (p60/460 years) 43/57 1.48 (0.57–3.83) 0.419
Sex (male/female) 59/41 0.29 (0.08–1.00) 0.050
T stage (1/2/3/4) 36/19/42/3 4.33 (1.78–10.50) 0.001
Fuhrman grade (I/II/III/IV) 18/39/26/13 3.07 (1.67–5.67) o0.001
ECOG-ps (0/X1) 86/14 2.56 (0.91–7.23) 0.075
UISS (low/intermediate/high) 22/69/9 5.72 (2.24–14.61) o0.001
C-reactive protein (p10/410mgl
 1) 58/42 5.85 (1.92–17.82) 0.002
Alive/dead 75/25
Cancer-specific/intercurrent disease 18/7
Table 3 The relationship between the presence of a preoperative
systemic inflammatory response and clinicopathological characteristics of
renal clear cell cancer
C-reactive
protein
C-reactive
protein
p10mgl
 1
(n¼58)
410mgl
 1
(n¼42) P-value
Age group (p60/460 years) 26/32 17/25 0.664
Sex (male/female) 36/22 23/19 0.463
Tumour stage (1/2/3/4) 28/12/18/0 8/7/24/3 0.003
Fuhrman grade (I/II/III/IV) 10/28/14/3 8/11/12/10 0.021
ECOG-ps (0/X1) 54/4 32/10 0.016
UISS (low/intermediate/high) 17/40/1 5/29/8 0.003
Cancer-specific survival (months)* 95.9 (89.8–102.0) 70.8 (57.8–83.8) o0.001
*Mean (95% CI).
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the role C-reactive in predicting survival following potentially
curative resection for renal cancer. Masuda et al (1998) in a
retrospective study of 111 patients reported that C-reactive
protein was a prognostic factor independent of tumour stage and
grade. However, performance status was not considered and
thresholds for C-reactive protein were not defined in the survival
analysis.
Few studies have identified factors which give prognostic
information in addition to the UISS criteria, namely T stage,
Fuhrman grade and ECOG-ps, in patients undergoing potentially
curative resection for renal cancer. Recently, Shvarts et al (2005)
reported that tumour p53 expression was related to Fuhrman
grade and displaced it in multivariate analysis. Similarly, Lam et al
(2005) reported that tumour Ki-67, unlike carbonic anhydrase, was
related to the degree of necrosis and had independent prognostic
value. Further studies are required to determine whether an
elevated C-reactive protein has prognostic value independent of
these other biological factors, in particular Ki-67.
It has been previously shown that, in patients undergoing
potentially curative surgery for colorectal and pancreatic cancer,
approximately one-third and one-half respectively, of patients had
elevated circulating concentration of C-reactive protein preopera-
tively and that these patients had a significantly lower cancer-
specific survival (McMillan et al, 2003; Jamieson et al, 2005). It was
of interest that, in the present study, the proportion of patients
with an elevated preoperative C-reactive protein concentration was
similar and that these patients also had a poorer outcome.
It may be that because C-reactive protein concentration
has prognostic value independent of UISS criteria, it might be
added to these criteria to improve the prediction outcome, in
particular the large group of ‘low or intermediate risk’ patients
with renal cancer. Indeed, this approach has recently been used to
improve the prediction of outcome in patients who underwent
potentially curative resection for colorectal cancer (Canna et al,
2004).
An elevated circulating C-reactive protein concentration is also
an established poor prognostic factor in patients with metastatic
renal cancer (Atzpodien et al, 2003; Bromwich et al, 2004;
Casamassima et al, 2005). In our previous study of patients
with metastatic renal cancer (Bromwich et al, 2004), approximately
70% had an elevated C-reactive protein (410mgl
 1) compared
with approximately 40% in the present study of primary operable
disease. This is consistent with previous observations that the
systemic inflammatory response increases with advancing disease
(Mahmoud and Rivera, 2002). However, the basis of the
independent relationship between an elevated C-reactive protein
concentration and poor survival in renal cancer is not clear. There
are a number of possible explanations. Firstly, that an elevated C-
reactive protein identifies tumours capable of producing signifi-
cant amounts of proinflammatory cytokines, in particular inter-
leukin-6 (Kinoshita et al, 1999; McKeown et al, 2004) and therefore
with the potential for more rapid growth of tumour cells (Jee et al,
2001; Trikha et al, 2003). Also, that an elevated C-reactive protein
identifies those patients with T-lymphocyte impairment (Maccio
et al, 1998; Canna et al, 2005) or patients with a proangiogenic
environment (Kofler et al, 2005; Xavier et al, 2006) allowing
unrestrained tumour growth and dissemination. Clearly, both
these tumour and host mechanisms may be related and required
for the greater malignant potential associated with an elevated
C-reactive protein concentration.
This is a relatively small, partially retrospective study and
requires verification in larger prospective cohorts. However, if
an elevated C-reactive protein concentration is shown to offer
prognostic value in addition to the current UISS criteria it would
improve our staging of these patients. Moreover, C-reactive
protein may offer a useful preoperative therapeutic target in
patients undergoing potentially curative surgery for renal clear cell
cancer.
In summary, the presence of a preoperative systemic inflam-
matory response predicts poor cancer-specific survival in patients
who have undergone potentially curative resection for renal clear
cell cancer.
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